C01B17/64

ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Anhydrous sodium thiosulfate and formulations thereof

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

METHOD OF PRODUCING SEMICONDUCTOR NANOPARTICLES

Provided is a method of producing semiconductor nanoparticles exhibiting band-edge emission with a short emission peak wavelength. The method of producing semiconductor nanoparticles comprises: obtaining a first mixture that contains a Ag salt, an In salt, a compound containing Ga and S, and an organic solvent; and performing a heat treatment of the first mixture at a temperature in a range of 125° C. or higher and 300° C. or lower to obtain first semiconductor nanoparticles.

ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Anhydrous sodium thiosulfate and formulations thereof

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONS

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

SODIUM THIOSULFATE-CONTAINING PHARMACEUTICAL COMPOSITIONS

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Process for treating a mixed feed of hydrogen sulfide gas and ammonia gas to produce ammonium thiosulfate and including methodology for emissions control

This invention relates to production of an aqueous solution containing ammonium thiosulfate from a feed gas containing hydrogen sulfide (H.sub.2S) and ammonia (NH.sub.3). Sufficient separation of feed gas H.sub.2S from NH.sub.3 is achieved by controlling individual NH.sub.3 and H.sub.2S absorption mass-transfer rates in a single co-current stage, whereby a first gas contacts a first liquid containing ammonium bisulfite (ABS). Substantially more NH.sub.3 is absorbed than H.sub.2S, converting ABS to diammonium sulfite (DAS). A portion of DAS reacts with a sufficiently small portion of H.sub.2S to produce ATS and leaves as a second liquid stream. A larger portion of H.sub.2S leaves as a second gas stream. The second gas stream is oxidized to sulfur dioxide (SO.sub.2) comprising a third gas stream. The third gas stream contacts the second aqueous stream in a second contact stage whereby DAS in the second liquid stream is converted to ABS and returned to the first contacting zone.

Process for treating a mixed feed of hydrogen sulfide gas and ammonia gas to produce ammonium thiosulfate and including methodology for emissions control

This invention relates to production of an aqueous solution containing ammonium thiosulfate from a feed gas containing hydrogen sulfide (H.sub.2S) and ammonia (NH.sub.3). Sufficient separation of feed gas H.sub.2S from NH.sub.3 is achieved by controlling individual NH.sub.3 and H.sub.2S absorption mass-transfer rates in a single co-current stage, whereby a first gas contacts a first liquid containing ammonium bisulfite (ABS). Substantially more NH.sub.3 is absorbed than H.sub.2S, converting ABS to diammonium sulfite (DAS). A portion of DAS reacts with a sufficiently small portion of H.sub.2S to produce ATS and leaves as a second liquid stream. A larger portion of H.sub.2S leaves as a second gas stream. The second gas stream is oxidized to sulfur dioxide (SO.sub.2) comprising a third gas stream. The third gas stream contacts the second aqueous stream in a second contact stage whereby DAS in the second liquid stream is converted to ABS and returned to the first contacting zone.